Human Microbiome Market: Biomedical Implications and Commercial Research Report

DALLAS, December 4, 2014 /PRNewswire/ --

ReportsnReports.com adds The Human Microbiome: Biomedical Implications and Birth of a Market 2014 research report of 94 pages to the pharmaceuticals intelligence collection of its industry research library.

The Human Microbiome: Biomedical Implications and Birth of a Market report focuses on biomedical aspects of human microbiome research, development, and commerce. It covers necessary background material, evolution of the field, progress in basic research, activities in the developing commercial market, deal activity, interviews with experts, and trends in microbiome research and commerce. Information for the report has been drawn from the scientific literature, discussions with knowledgeable individuals, and an online survey of people working in this area. It covers the evolution of microbiome research and its growth in the commercial market. Specific areas of study include microbial ecology, systems biology, diet, diagnostics, contributions in health and disease, and infectious disease. Complete research is available at http://www.reportsnreports.com/reports/319916-the-human-microbiome-biomedical-implications-and-birth-of-a-market.html .

Projects now in various stages of commercial development cover a broad spectrum of applications. This report covers descriptions and activities of 23 microbiome companies. The most prevalent applications fall in the category of live biotherapeutic agents (probiotics to some) that deal with various diseases and disorders. These include Crohn's disease, skin ulcers, acne, diabetes, inflammatory bowel disease, and C. difficile gastroenteritis. Some programs in this category address broader disease or health maintenance issues including: autoimmune disease, cholesterol reduction, metabolic diseases, the immune system, and infectious disease. Two companies work to engineer commensal bacteria that can enter the microbiome and generate therapeutic molecules in situ for treatment of inflammatory bowel disease, mucositis, and infectious diseases. Several organizations are developing microbiome-based diagnostic products, which include biomarkers for Crohn's disease, colon cancer, and pre-term labor risk.

The report also describes 12 recent microbiome-related deals. Of these, five involve research collaborations between small companies and big pharmas. J&J's Janssen Biotech unit is active in three of these deals, Pfizer in one, and Merck in another. The Mayo Clinic Center for Personalized Medicine has been active in the microbiome space, providing funds and collaborative support to three small companies. In two instances large companies have provided research funds to academic groups. Other arrangements include small companies working together, another collaborating with a large clinical lab services firm, and another which has been granted a technology license.

Our online survey of 63 people active in microbiome work divides about evenly between those in commerce and academia. About three-quarters of respondents are managers or principal investigators. Nearly half are connected to work on inflammation, and a third are involved with metabolic diseases. About three-quarters of respondents feel that levels of microbiome-related activities in their organization would stay about the same or increase during the next two years. Two-thirds of respondents felt that sufficient microbiome-related information is now available to justify translational efforts, while one-third disagreed. Two-thirds felt optimistic that microbiome work will provide major contributions to healthcare, while nearly a third said it's too early to tell. Nearly two-thirds agreed that big pharma will become heavily involved in microbiome work over the next decade, and only 15% disagreed.

In addition to covering several aspects of the microbiome, the report also includes the impact of this rising field on commercial aspects and product development. Companies covered in this space include 4D Pharma, ActoGenixAOBiome, AvidBiotics, CIPAC Limited, Enterome Bioscience, Human Longevity, Metabiomics, Microbiome Therapeutics, Miomics, OmniBiome Therapeutics, OptiBiotix, Osel Inc, OxThera, PathoGenetix, Rebiotix, Ritter Pharmaceuticals, Second Genome, Seres Health, uBiome, UCB, UC San Francisco, Vedanta, ViThera Pharmaceuticals and Whole Biome. Order a copy of this research at http://www.reportsnreports.com/Purchase.aspx?name=319916 .

This research provides in-depth analysis of market data as well as exclusive interview transcripts with the experts like Peter DiLaura, President & CEO, Second Genome, Colleen Cutcliffe, CEO, Whole Biome, James Brown, PhD; Head, Computational Biology; Head, Microbiome Matrix Team; GlaxoSmithKline, Jack Gilbert, PhD., Environmental Microbiologist, Assoc. Prof., Department of Ecology & Evolution, Argonne National Laboratory, Glenn Tillotson, PhD, Senior Partner, Transcrip Partners, USA, Peter P. Lee, MD, Executive Chairman, Osel, Inc., Gregory Kuehn, VP Business Development and Marketing, Metabiomics, Stephen Elms, CEO, Miomics Bio-Therapeutics and Sydney M. Finegold, M.D., Emeritus Professor of Medicine, and Emeritus Professor of Microbiology, Immunology, and Molecular Biology, UCLA School of Medicine; Staff Physician, Infectious Disease Section, VA Greater Los Angeles Healthcare System.

The Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies 2014 market research report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy.  This research covers three principle therapies that have been in the works for cancer patients: checkpoint inhibitors, anticancer vaccines and adoptive cellular immunotherapy. The report is further coupled with an in-depth introduction and history as well as with data for market outlook. Also featured in this report are exclusive interviews with three high-end professors, researchers and CEOs: 1. Adil Daud, MD, Clinical Professor, Department of Medicine (Hematology/Oncology), University of California at San Francisco (UCSF); Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center. 2. Matthew Lehman, Chief Executive Officer, Prima BioMed (a therapeutic cancer vaccine company with headquarters in Sydney, Australia) and 3. Marcela Maus, MD, PhD, the Director of Translational Medicine and Early Clinical Development, Translational Research Program, Abramson Cancer Center, University of Pennsylvania in Philadelphia. Complete report is available at http://www.reportsnreports.com/reports/319917-cancer-immunotherapy-immune-checkpoint-inhibitors-cancer-vaccines-and-adoptive-t-cell-therapies.html .

Explore more reports on pharmaceuticals market and other newly published research by the same publisher at http://www.reportsnreports.com/publisher/chi-healthtech/ .

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@reportsandreports.com  

Connect With Us on:  

Facebook:  https: //www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn:  www.linkedin.com/company/reportsnreports

Twitter:  https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest:  www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds:  http: //www.reportsnreports.com/feed/l-latestreports.xml